<DOC>
	<DOCNO>NCT01898845</DOCNO>
	<brief_summary>This study evaluate safety tolerability estimate MTD and/or recommend dose expansion .</brief_summary>
	<brief_title>A Phase I Study LEE011 Asian Patients</brief_title>
	<detailed_description>This multi-center , open label , dose finding , phase I study oral single agent LEE011 , administer daily .</detailed_description>
	<criteria>Patient histologically confirm diagnosis solid tumor ECOG PS &lt; 2 Good organ function screen visit A sufficient interval mast elapse last dose prior anticancer therapy Impairment GI function Patients concurrent severe and/or uncontrolled concurrent medical condition Known diagnosis HIV active viral hepatitis Pregnant nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Neoplasms</keyword>
</DOC>